Palm Research Center
Las Vegas, Nevada 89148
3 studies enrolling now · 35 studies all time
What they study most
Acromegaly, Adult Growth Hormone Deficiency, Body Weight, Cardiovascular Diseases, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Neuropathy Peripheral, Gastroparesis, Heart Failure, Hyperlipidemia
Studies at this site
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
- A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) — Recruiting now
- Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry) — Recruiting now
- Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes — Running, not enrolling
- Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo — Running, not enrolling
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly — Completed
- Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt — Completed
- Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus — Completed
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly — Completed
- Effect of the FreeStyle Libre 2 Flash Glucose Monitoring System on Hyperglycemia in People With T2 Diabetes — Completed
- A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. — Completed
- Versartis International Trial in Adults With Long-Acting Growth Hormone — Completed
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
- A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
- A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes — Completed
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 — Stopped early
- Diabetic Gastroparesis Study 05 — Stopped early
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 — Stopped early
- Prediabetes and Type 2 Diabetes Data Collection Study — Status unconfirmed
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 — Stopped early
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed
- Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) — Completed
- A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus — Completed
- A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy — Completed
- Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy — Completed
- An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus — Completed
- A Study of LY900014 in Participants With Type 1 Diabetes — Completed
- An Open-Label Trial of PEMF Therapy [Provant Infinity Therapy System] for Home Use in Postoperative Pain — Withdrawn before enrolling
- A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes — Completed
- Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro — Withdrawn before enrolling
- A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus — Stopped early
- A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol — Stopped early
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus — Completed
- Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) — Completed
- Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed